Drug intelligence / Profile preview

DNX-5000

Development stage: Preclinical
Lead developer: Dynamix Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

DNX-5000 is a preclinical-stage small molecule drug candidate developed by Dynamix Pharmaceuticals. It functions as a dual inhibitor of Focal Adhesion Kinase (FAK) and Proline-rich Tyrosine Kinase 2 (PYK2). Discovered using the company's proprietary DynamixFit™ technology platform, DNX-5000 is designed as a Type II kinase inhibitor. The drug is being investigated for the treatment of various cancers, where FAK and PYK2 signaling promotes tumor cell migration and survival, as well as for metabolic bone diseases such as osteoporosis, where these kinases play a role in bone remodeling and osteoclast activity.

Targets

FAK (Focal adhesion kinase)PTK2B

Beyond the preview

Go deeper on DNX-5000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNX-5000.

Explore the full profile